Processes for treating coral and coating an object

• US 7,258,898 B2
• Filed: 11/14/2001
• Issued: 08/21/2007
• Est. Priority Date: 11/16/2000
• Status: Expired due to Term

• Current Assignee: Biotomo Pty., Ltd.
• Original Assignee: Nanocoatings Pty., Ltd.
• Inventors: Russell, Jennifer, Ben-Nissan, Besim, Hu, Ji, Trefry, Clifford, Conway, Robert M., Gillott, Edit, Milev, Adriyan S., Kannangara, G. S. Kamall, Green, Douglas Drysdal
• Primary Examiner(s): Page; Thurman K.
• Assistant Examiner(s): NWAONICHA, CHUKWUMA O
• Application Number:
  US10/416,920
• Publication Number:
  US 20040091547A1
• Time in Patent Office: 2,106 Days
• Field of Search: 427/301, 427/299, 427/304, 427/314, 427/316, 423/305
• US Class Current: 427/301
• CPC Class Codes: A61L 27/12 Phosphorus-containing materials, e.g. apatite
• CPC Class Codes: C01B 25/32 Phosphates of magnesium, calcium, strontium, or barium
• CPC Class Codes: C07F 9/1417 Compounds containing the structure P-O-C(=X)- (X = O, S, Se)
• CPC Class Codes: C07F 9/4093 Compounds containing the structure P(=X)-X-C(=X)- (X = O, S, Se)

Abstract

The present invention generally relates to an improved process for the hydrothermal conversion of coral into hydroxyapatite, a process for coating an object with hydroxyapatite, a process for coating an object with a divalent metal phosphate and uses of objects prepared by these processes. Following the processes according to the present invention, the resultant hydroxyapatite has greater strength and bioactivity than that of the coral prior to its conversion.

Claims

1. A process for coating an object with a divalent metal phosphate, the process comprising the steps of:

(a) preparing a sol containing a divalent metal phosphonate complex wherein a divalent metal is coordinated to a phosphonate compound according to formula (1)

R—

C(O)—

O—

P(O)R¹—

O—

C(O)—

.R² 

 

(1)

wherein R, R¹ and R², which may be the same or different, are selected from the group consisting of hydrogen, substituted alkyl groups and unsubstituted alkyl groups; and

(b) dipping the object into the sol;

(c) heating the dipped object in order to remove any solvent; and

(d) firing the heated object to allow conversion of the divalent metal phosphonate complex into the divalent metal phosphate.

2. The process of claim 1, wherein R and R² are CH₃.

3. The process of claim 1, wherein R¹ is hydrogen.

4. The process of claim 1, wherein the divalent metal is selected from the group consisting of calcium, magnesium, strontium, copper, manganese and zinc.

5. The process of claim 4, wherein the divalent metal is calcium.

6. The process of claim 1, wherein the divalent metal is coordinated with a carbonyl and/or phosphoryl oxygen of the phosphonate.

7. The process of claim 1, wherein the divalent metal phosphonate is a six-membered chelate ring according to formula (2) or (3)

8. The process of claim 1, wherein the divalent metal phosphonate complex has a structure according to formula (4) or (5)

9. The process according to claim 1, wherein the object is formed from the group consisting of one or more of coral, hydroxyapatite converted from coral, hydroxyapatite, titanium, cobalt, chromium, molybdenum, vitallium alloy, zirconium, alloys, surgical stainless steels, alumina (Al₂O₃), zirconia (PSZ), silicon nitride (Si₃N₄), sialons and bioglasses.

10. The process according to claim 1, wherein the coating covers meso- and nano-pores of the object.

11. The process according to claim 1, wherein in step (c) the object is heated to between about 20°

C. and 200°

C.

12. The process according to claim 11, wherein in step (c) the object is heated to about 130°

C.

13. The process according to claim 1, wherein in step (d), the object is fired at between about 500°

C. and 1200°

C.

14. The process according to claim 1, further comprising incorporating one or more pharmaceutically active compounds in the coating.

15. The process according to claim 1, wherein the pharmaceutically active compounds are selected from the group consisting of bone morphogenic proteins (BMP), collagen, growth factors (GF), and marrow stromal cells (MSC).